Avalo Therapeutics (AVTX) Receivables (2016 - 2023)

Avalo Therapeutics (AVTX) has 8 years of Receivables data on file, last reported at $44000.0 in Q2 2023.

• For the quarter ending Q2 2023, Receivables fell 97.62% year-over-year to $44000.0; the trailing twelve-month figure through Jun 2023 stood at $44000.0 (down 97.62% YoY), and the FY2022 full-year result was $1.9 million, down 6.84% from the prior year.
• Receivables for Q2 2023 stood at $44000.0, down from $1.9 million in the prior quarter.
• Across five years, Receivables topped out at $8.2 million in Q1 2019 and bottomed at $44000.0 in Q2 2023.
• The 5-year median for Receivables is $4.3 million (2020), against an average of $3.9 million.
• The widest annual swing landed in 2020, when Receivables surged 32.68%; it then sank 97.62% in 2023.
• A 5-year view of Receivables shows it stood at $5.2 million in 2019, then dropped by 16.35% to $4.4 million in 2020, then climbed by 9.44% to $4.8 million in 2021, then slumped by 60.01% to $1.9 million in 2022, then slumped by 97.71% to $44000.0 in 2023.
• The last three Receivables figures came in at $44000.0 (Q2 2023), $1.9 million (Q4 2022), and $1.3 million (Q3 2022), per Business Quant data.

Peer Comparison